See more : Samsung Publishing Co., Ltd (068290.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Calyxt, Inc. (CLXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calyxt, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Setco Automotive Limited (SETCO.BO) Income Statement Analysis – Financial Results
- Pacific Gas and Electric Company PFD 1ST 4.36% (PCG-PI) Income Statement Analysis – Financial Results
- Spirit Blockchain Capital Inc. (SPIR.CN) Income Statement Analysis – Financial Results
- The TJX Companies, Inc. (0LCE.L) Income Statement Analysis – Financial Results
- C.H. Robinson Worldwide Inc (CH1A.DE) Income Statement Analysis – Financial Results
Calyxt, Inc. (CLXT)
About Calyxt, Inc.
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 0.00 | 28.56M | 35.13M | 9.28M | 0.00 | 0.00 | 200.00K | 751.00K |
| Gross Profit | 157.00K | -2.57M | -11.28M | -1.98M | 236.00K | 508.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 100.00% | -9.89% | -47.28% | -27.19% | 100.00% | 100.00% | 49.87% | 40.96% |
| Research & Development | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 5.57M | 45.00K | 252.00K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 1.53M | 810.00K | 3.24M | 3.21M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -22.37M | -28.52M | -40.59M | -36.47M | -28.12M | -25.79M | -11.74M | -5.48M |
| EBITDA Ratio | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,830.08% | -5,005.51% | -2,941.35% | -430.90% |
| Operating Income | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -7.09M | -114.00K | 1.56M | 1.49M | 1.48M | -190.00K | 28.00K | 186.00K |
| Net Income | -9.80M | -29.09M | -46.40M | -41.10M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -6,243.95% | -111.92% | -194.54% | -563.35% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| EPS Diluted | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| Weighted Avg Shares Out | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
| Weighted Avg Shares Out (Dil) | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
CALYXT INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Calyxt, Inc. – CLXT
NEW ORLEANS, March 9, 2023 /PRNewswire/ — Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Calyxt, Inc. (“the Company”) (NasdaqCM: CLXT)...
What Penny Stocks Trends Can Help You Profit in 2023?
How to make money with penny stocks in 2023 The post What Penny Stocks Trends Can Help You Profit in 2023? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Penny Stocks To Watch After Big News This Week
Penny stocks to watch with news that are turning heads in the stock market this week. The post 5 Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information |...
Why Is Calyxt (CLXT) Stock Up 140% Today?
Calyxt (NASDAQ: CLXT ) stock is rocketing higher on Tuesday after the company signed a merger agreement with Cibus Global. Calyxt and Cibus Global both operate in the agriculture-based gene editing sector.
Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company
– The merger will bring together the technology platforms and facilities of two pioneering companies to create a leader in precision gene editing focused on driving sustainable agriculture and the availability of renewable low-carbon ingredients – – Upon closure of...
Calyxt, Inc. (CLXT) Q3 2022 Earnings Call Transcript
Calyxt, Inc. (NASDAQ:CLXT ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants William Koschak - CFO Michael Carr - President and CEO Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome...
Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates
Calyxt (CLXT) delivered earnings and revenue surprises of 13.33% and 86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Calyxt, Inc. (CLXT) CEO Michael Carr on Q2 2022 Results - Earnings Call Transcript
Calyxt, Inc. (NASDAQ:CLXT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and Chief Executive Officer Conference Call Participants Bobby Burleson - Canaccord Amit Dayal...
Calyxt to Present at the Canaccord Genuity 42nd Annual Growth Conference
ROSEVILLE, Minn. , July 28, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A.
Calyxt to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time
ROSEVILLE, Minn. , July 21, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, August 4, 2022, at 4:30 p.m.
Source: https://incomestatements.info
Category: Stock Reports